TY - JOUR
T1 - Bile acid-activated receptors in innate and adaptive immunity
T2 - targeted drugs and biological agents
AU - Cheung, Kenneth Chat Pan
AU - Ma, Jiao
AU - Loiola, Rodrigo Azevedo
AU - Chen, Xingxuan
AU - Jia, Wei
N1 - Funding Information:
The work was funded by HKBU Strategic Development Fund (Grant Number: SDF 19‐1216‐P03); France/Hong Kong Joint Research Scheme (Grant Number: F‐HKBU201/22, PROCORE); RC's Startup Grant (Tier 1) (Grant Number: AY2020/21).
Publisher Copyright:
© 2023 The Authors. European Journal of Immunology published by Wiley-VCH GmbH.
PY - 2023/8
Y1 - 2023/8
N2 - Bile acid-activated receptors (BARs) such as a G-protein bile acid receptor 1 and the farnesol X receptor are activated by bile acids (BAs) and have been implicated in the regulation of microbiota-host immunity in the intestine. The mechanistic roles of these receptors in immune signaling suggest that they may also influence the development of metabolic disorders. In this perspective, we provide a summary of recent literature describing the main regulatory pathways and mechanisms of BARs and how they affect both innate and adaptive immune system, cell proliferation, and signaling in the context of inflammatory diseases. We also discuss new approaches for therapy and summarize clinical projects on BAs for the treatment of diseases. In parallel, some drugs that are classically used for other therapeutic purposes and BAR activity have recently been proposed as regulators of immune cells phenotype. Another strategy consists of using specific strains of gut bacteria to regulate BA production in the intestine.
AB - Bile acid-activated receptors (BARs) such as a G-protein bile acid receptor 1 and the farnesol X receptor are activated by bile acids (BAs) and have been implicated in the regulation of microbiota-host immunity in the intestine. The mechanistic roles of these receptors in immune signaling suggest that they may also influence the development of metabolic disorders. In this perspective, we provide a summary of recent literature describing the main regulatory pathways and mechanisms of BARs and how they affect both innate and adaptive immune system, cell proliferation, and signaling in the context of inflammatory diseases. We also discuss new approaches for therapy and summarize clinical projects on BAs for the treatment of diseases. In parallel, some drugs that are classically used for other therapeutic purposes and BAR activity have recently been proposed as regulators of immune cells phenotype. Another strategy consists of using specific strains of gut bacteria to regulate BA production in the intestine.
KW - bile acid
KW - intestinal macrophage
KW - GPBAR1
KW - FXR
KW - ROR-γ
UR - http://www.scopus.com/inward/record.url?scp=85162655094&partnerID=8YFLogxK
U2 - 10.1002/eji.202250299
DO - 10.1002/eji.202250299
M3 - Review article
SN - 0014-2980
VL - 53
JO - European Journal of Immunology
JF - European Journal of Immunology
IS - 8
M1 - 2250299
ER -